Overview

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

Status:
Completed

Trial end date:
2019-05-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to provide access to palbociclib in Mexico and in selected Latin American countries before it becomes commercially available to patients with HR positive/HER2-negative ABC who are appropriate candidates for letrozole therapy.

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Letrozole
Palbociclib